Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Current Assets (2016 - 2025)

Gsk has reported Current Assets over the past 10 years, most recently at $23.3 billion for Q4 2025.

  • Quarterly results put Current Assets at $23.3 billion for Q4 2025, up 6.76% from a year ago — trailing twelve months through Dec 2025 was $23.3 billion (up 6.76% YoY), and the annual figure for FY2025 was $23.3 billion, up 6.76%.
  • Current Assets for Q4 2025 was $23.3 billion at Gsk, up from $21.8 billion in the prior quarter.
  • Over the last five years, Current Assets for GLAXF hit a ceiling of $25.2 billion in Q4 2021 and a floor of $21.8 billion in Q4 2024.
  • Median Current Assets over the past 5 years was $23.3 billion (2025), compared with a mean of $23.6 billion.
  • Biggest five-year swings in Current Assets: dropped 5.84% in 2021 and later rose 6.76% in 2025.
  • Gsk's Current Assets stood at $25.2 billion in 2021, then dropped by 3.23% to $24.4 billion in 2022, then decreased by 5.01% to $23.1 billion in 2023, then dropped by 5.72% to $21.8 billion in 2024, then rose by 6.76% to $23.3 billion in 2025.
  • The last three reported values for Current Assets were $23.3 billion (Q4 2025), $21.8 billion (Q4 2024), and $23.1 billion (Q4 2023) per Business Quant data.